•  
  •  
  •  
  •  

2026-08-12 10:00:57

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  UnichemLaboratories

Stock Report

  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • Unichem Laboratories Ltd pays fine of Euro 16,753,873.41 to European Commission
  • Unichem Laboratories Ltd receives EIR from USFDA classifying Roha API facility as VAI
  • Unichem Laboratories Ltd receives Form 483 from USFDA with 3 observations for Roha API facility
  • Unichem Laboratories Ltd receives 4 observations from USFDA for Pithampur API facility
  • Unichem Laboratories Ltd gets 5 observations from USFDA for Goa formulation facility
  • Unichem Laboratories Ltd consolidated Q3 FY24 PAT rises to Rs. 83.99 crores
  • Unichem Laboratories Ltd receives ANDA approval for Doxazosin Tablets
  • Unichem Laboratories Ltd receives ANDA approval for Prasugrel Tablets
  • Unichem Laboratories Ltd Q1FY24 consolidated loss at Rs. 66.83 lakhs
  • Unichem Laboratories Ltd Q4 FY2023 consolidated loss at Rs. 44.26 crores
  • Ipca Laboratories Ltd to acquire majority stake in Unichem Laboratories Ltd
  • Unichem Laboratories Ltd appoints Ms. Priti Puri as additional independent director
  • Unichem Laboratories Ltd receives ANDA approval for Ranolazine Extended-Release Tablets
  • Unichem Laboratories Ltd consolidated Q3FY23 loss at Rs. 63.92 crores
  • Unichem Laboratories receives ANDA approval for Extended Phenytoin Sodium Capsules
  • Unichem Laboratories Ltd sells 1st tranche of stake in Optimus for Rs. 270.98 crores
  • ICRA downgrades Unichem Laboratories' rating for Rs. 176 crs bank facilities
  • Unichem Laboratories receives ANDA approval from USFDA for Carbamazepine Tablets USP
  • Unichem Laboratories receives ANDA Approval for Quetiapine Extended-Release Tablets
  • Unichem Laboratories receives ANDA approval for Labetalol Hydrochloride Tablets
  • Unichem Laboratories Ltd Q1 FY2023 consolidated loss at Rs. 23.36 crores
  • Unichem Laboratories Ltd reports surge in Q4FY22 consolidated PAT to Rs. 71.47 crores
  • Unichem Laboratories Ltd Board recommends Dividend of Rs. 4

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025